Dawn of a New RAMPage.
Receptor activity-modifying proteins (RAMPs) interact with G-protein-coupled receptors (GPCRs) to modify their functions, imparting significant implications upon their physiological and therapeutic potentials. Resurging interest in identifying RAMP-GPCR interactions has recently been fueled by coevolution studies and orthogonal technological screening platforms. These new studies reveal previously unrecognized RAMP-interacting GPCRs, many of which expand beyond Class B GPCRs. The consequences of these interactions on GPCR function and physiology lays the foundation for new molecular therapeutic targets, as evidenced by the recent success of erenumab. Here, we highlight recent papers that uncovered novel RAMP-GPCR interactions, human RAMP-GPCR disease-causing mutations, and RAMP-related human pathologies, paving the way for a new era of RAMP-targeted drug development.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Signal Transduction
- Receptors, G-Protein-Coupled
- Receptor Activity-Modifying Proteins
- Pharmacology & Pharmacy
- Mutation
- Molecular Targeted Therapy
- Humans
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Calcitonin Gene-Related Peptide
- Antibodies, Monoclonal, Humanized
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Signal Transduction
- Receptors, G-Protein-Coupled
- Receptor Activity-Modifying Proteins
- Pharmacology & Pharmacy
- Mutation
- Molecular Targeted Therapy
- Humans
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Calcitonin Gene-Related Peptide
- Antibodies, Monoclonal, Humanized